News

Founding investor Versant Ventures co-led the round with MPM Capital. They were also joined by other syndicate investors including Fonds de solidarité FTQ, Celgene Switzerland, an affiliate of

Lilly's new space will help foster and accelerate the discovery of medicines within the company's core therapeutic areas of immunology, diabetes, oncology and neurodegeneration, as well as the

The topline results from the trial have showed that the drug in combination with standard of care ACZ885 reduces the risk of major adverse cardiovascular events (MACE), a

Shingrix is being developed for the prevention of shingles, better known than herpes zoster, a painful, itchy rash condition caused by reactivation of latent chickenpox virus. The vaccine

ImmunoCellular has determined that the Company is unable at this time to secure sufficient additional financial resources to complete the phase 3 registration trial of ICT-107. As a

Rubius has developed the technology to grow, genetically engineer and mature long-circulating red cell therapeutics which will provide transformational clinical benefits to a wide range of patients across

Mydayis is a once-daily treatment and prescription medicine, which includes three different types of drug-releasing beads to control ADHD in patients 13 years and older. Shire plans to

The companies plan to initiate a Phase 2 open-label, randomized, non-comparative study to evaluate the safety, tolerability and efficacy of eFFECTOR’s investigational small molecule MNK1/2 inhibitor, eFT508, in

The event organized to mark the collaboration and the granting of the loan occurs today at the EIB Headquarters in Luxembourg, in presence of Mr. Ambroise Fayolle, EIB